WO2019186786A1 - Treatment method - Google Patents
Treatment method Download PDFInfo
- Publication number
- WO2019186786A1 WO2019186786A1 PCT/JP2018/012839 JP2018012839W WO2019186786A1 WO 2019186786 A1 WO2019186786 A1 WO 2019186786A1 JP 2018012839 W JP2018012839 W JP 2018012839W WO 2019186786 A1 WO2019186786 A1 WO 2019186786A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- energy
- blood vessel
- treatment
- treatment method
- intestinal tract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
Definitions
- the present invention relates to a treatment method for enhancing peristaltic movement of the intestinal tract.
- Constipation is a common illness that is frequently observed worldwide and is said to affect 25-30% of the population.
- Chronic constipation is defined as having bowel movements less than 3 times a week and having difficulty in defecation. It is known that the decrease in the number of defecations may cause symptoms such as abdominal fullness and abdominal pain, difficulty of defecation, discomfort during defecation, frequent frequent stools, and so on, which significantly impairs the social activity and mental health of patients.
- chronic constipation includes primary (idiopathic) and secondary. Secondary is caused by organic diseases such as colorectal cancer, caused by drugs such as opioids used for pain relief, and associated with systemic diseases such as neurological diseases and collagen diseases.
- primary (idiopathic) constipation is divided into organic constipation and functional constipation depending on the presence or absence of organic abnormalities (such as dilation) in the colon.
- functional constipation with no organic abnormalities in the colon, the bowel movement of the large intestine is reduced, so that the stool transit time is delayed and the constipation is seen as ⁇ colon transit time delay type
- the effectiveness of oral treatment is particularly poor for these patients. Total colectomy or partial excision may be recommended for patients with severe constipation who are refractory to oral treatment, but it is not widely accepted because of its invasiveness.
- the inventors of the present invention have found an effective and minimally invasive treatment method for various symptoms and diseases caused by a decrease or insufficiency of peristaltic movement of the intestinal tract.
- the treatment method according to the present invention includes enhancing peristaltic movement of the intestinal tract by performing a treatment that reduces the activity of the autonomic nerve in a blood vessel having a peripheral nerve that performs innervation of the patient's intestinal tract.
- the peristaltic movement of the patient's intestinal tract can be enhanced.
- FIG. 1 schematically shows a procedure of a treatment method (hereinafter referred to as “treatment method”) according to the embodiment in a flowchart.
- the treatment method generally includes delivering a predetermined medical device into a blood vessel for performing the treatment (S11) and performing the treatment within the blood vessel (S12). .
- the blood vessel V that performs the treatment method will be described.
- the symbol VR indicates the right renal artery
- the symbol VL indicates the left renal artery.
- Reference sign Va indicates the superior mesenteric artery
- reference sign Vb indicates the celiac artery
- reference sign Vc indicates the inferior mesenteric artery.
- the blood vessel V to which the treatment method is applied may be able to enhance the peristaltic movement of the intestinal tract of the patient (subject) by being subjected to the predetermined treatment according to the embodiment (for example, application of energy described later).
- the predetermined treatment for example, application of energy described later.
- at least one of the superior mesenteric artery Va, the celiac artery Vb, and the inferior mesenteric artery Vc can be suitably selected.
- the treatment site (range, position, etc.) where treatment is performed in the blood vessel V is not particularly limited as long as the peristaltic movement of the intestinal tract can be enhanced.
- treatment may be performed on an arbitrary range (part) in the traveling direction (extending direction) of the blood vessel V, or in the circumferential direction of the blood vessel V (circumferential direction in the cross section). Treatment may be performed on the range (site).
- the treatment may be performed a plurality of times for a plurality of treatment sites of the same blood vessel V, or may be performed a plurality of times for any treatment site of different blood vessels V. .
- the treatment method according to the present embodiment is capable of enhancing the peristaltic movement of the patient's intestinal tract by performing at least one treatment, so that the type of blood vessel to be treated, the treatment site of the blood vessel, the treatment
- the treatment There are no particular restrictions on the specific contents, devices and instruments used for the treatment.
- the medical device 100 used for the treatment method and treatment method which concern on this embodiment is demonstrated.
- an example in which treatment is performed on the superior mesenteric artery Va as the blood vessel V to be treated will be described.
- the procedure described below is merely an example, and for example, a procedure known in the medical field can be appropriately adopted as a part of the procedure or a procedure not particularly described.
- FIG. 3 is a cross-sectional view (longitudinal cross-sectional view) schematically showing a state in the blood vessel V when the treatment method is being performed
- FIG. 4 is a view inside the blood vessel V when the treatment method is being performed.
- It is sectional drawing (transverse sectional view) which shows a mode typically. 3 and 4, the traveling direction of the blood vessel V is indicated by an arrow X, the depth direction orthogonal to the traveling direction of the blood vessel V is indicated by an arrow Y, and each of the traveling direction of the blood vessel V and the depth direction of the blood vessel V is illustrated.
- An orthogonal direction is indicated by an arrow Z.
- an operator such as a doctor (hereinafter referred to as “operator”) has an autonomic nerve in a blood vessel V having a peripheral nerve (plexus) Sa that performs innervation of the intestinal tract of the patient.
- a peripheral nerve plexus
- peristaltic movement of the intestinal tract is increased.
- the surgeon can perform at least one symptom of abdominal bloating, abdominal pain, perineal discomfort, and frequent stool due to abnormal constipation and / or peristaltic movement of the intestinal tract. Helps alleviate (at least one of a group of symptoms caused by an alleviation of patient constipation and / or abnormal intestinal peristalsis).
- the surgeon applies energy to one surrounding nerve Sa or a plurality of surrounding nerves Sa as a treatment.
- the surgeon increases the peristaltic movement of the intestinal tract by damaging the peripheral nerve Sa and completely or partially blocking the autonomic nerve transmission to the digestive tract by the peripheral nerve Sa.
- the following points can be considered as reasons why the peristaltic movement of the intestinal tract is activated by performing a treatment for reducing the activity of the autonomic nerve in the blood vessel V having the surrounding nerve Sa.
- the peripheral nerve Sa is damaged by the energy applied from within the blood vessel V, and the autonomic nerve transmission to the digestive tract by the peripheral nerve Sa is completely or partially blocked, the sympathetic nervous system is relative to the sympathetic nervous system and parasympathetic nervous system. It becomes attenuated and becomes parasympathetic dominant.
- intestinal motility is controlled autonomously in the periphery, but the enteric nervous system becomes dominant, and peristaltic movement of the intestinal tract is activated.
- intestinal peristaltic movement promotes and normalizes the colon transit time, so that abdominal fullness, abdominal pain, perineal discomfort, frequent stool due to abnormal constipation and / or intestinal peristaltic movement Alleviation of at least one of the symptoms is promoted.
- intestinal peristalsis movement of the large intestine is reduced in functional constipation with no organic abnormality in the colon, and therefore, the stool passage time is delayed and constipation is observed. It is possible to favorably alleviate the symptoms of colon transit time delayed constipation.
- the surgeon can perform treatment using a predetermined medical device 100 as shown in FIGS. 3 and 4, for example. Specifically, the surgeon can perform a treatment by operating the medical device 100 in a state where the medical device 100 including the energy transmission member 120 capable of applying energy is disposed in the blood vessel V. 3 and 4, energy applied by the medical device 100 is schematically indicated by a dotted arrow.
- a catheter device including an elongated catheter body 110 and an energy transmission member 120 disposed at the distal end portion of the catheter body 110 (near the end portion on the insertion direction side in the blood vessel V).
- the catheter main body 110 includes a lumen (not shown) extending in the major axis direction (extending direction) of the catheter main body 110 and a proximal end portion of the catheter main body 110 (in the vicinity of the end opposite to the insertion direction into the blood vessel V). And a hub (not shown).
- the medical device 100 can insert a medical instrument such as a guide wire 200 or distribute a liquid such as a priming liquid through a lumen and a hub.
- the energy transmission member 120 included in the medical device 100 is, for example, simple high frequency, bipolar high frequency, high-density focused ultrasound, ultrasonic, microwave, light, heat, cold radiation, engineering therapy, magnetic, electrical, electromagnetic , Cryotherapy, plasma, mechanical energy, chemical energy, kinetic energy, potential energy, nuclear energy, elastic energy, hydrodynamic energy from the inside of blood vessel V It can be configured to be granted.
- the operation of the energy transmission member 120 can be controlled, for example, via a controller (control device) (not shown).
- a controller for example, a known control device including a CPU and a storage unit can be used.
- the storage unit includes a ROM that stores various programs and data, a RAM that temporarily stores programs and data as a work area, and a hard disk that can store various programs and data. A series of programs necessary for operation control of the medical device 100 can be stored in the storage unit.
- the energy transmission member 120 is electrically connected to a power supply unit (not shown), and can control ON / OFF of the operation, the magnitude of energy applied to the blood vessel V, and the like via the power supply unit.
- the treatment according to the present embodiment may be performed by a medical device such as a treatment robot that replaces the work performed by the operator. In this case, for the treatment, an operator or the like may control the treatment robot at a medical site such as an operating room, or may control the treatment robot at a remote place.
- the catheter body 110 included in the medical device 100 follows a curved or bent portion of a patient's blood vessel in order to deliver the energy transmission member 120 to the superior mesenteric artery Va, the celiac artery Vb, or the inferior mesenteric artery Vc. Therefore, it is preferable that the mobile phone is configured to be movable.
- the catheter body 110 employs, for example, various materials and structures used for known catheter devices having flexibility, torque transmission, kink resistance, and the like. be able to.
- the surgeon can use, for example, a guide wire 200 and a guide catheter 300 as shown in FIG.
- the guide wire 200 and the guide catheter 300 those known in the medical field can be used.
- the surgeon wants the medical device 100 to be a blood vessel V (any blood vessel of the superior mesenteric artery Va, the celiac artery Vb, the inferior mesenteric artery Vc) via, for example, the femoral artery, the abdominal aorta, or the like.
- a blood vessel V any blood vessel of the superior mesenteric artery Va, the celiac artery Vb, the inferior mesenteric artery Vc
- the surgeon delivers the energy transmission member 120 to a desired position in the blood vessel V, and then operates the energy transmission member 120 so that the surrounding nerves existing outside the blood vessel V from inside the blood vessel V are operated.
- Energy is given to Sa.
- the surgeon when performing treatment, for example, the surgeon, for example, in the entire circumferential direction of the blood vessel V (a form in which there is no intermittence along the inner wall of the blood vessel V), a part of the circumferential direction of the blood vessel V (the circumferential direction of the inner wall of the blood vessel V) Only a part, for example, a form less than a half circumference), a half circumference of the blood vessel V (a half form in the circumferential direction of the inner wall of the blood vessel V), a linear shape (a form continuous in a certain length in the circumferential direction of the inner wall of the blood vessel V) , And energy (in a direction away from the center of the cross section of the blood vessel V outward in the radial direction of the blood vessel V).
- the surgeon can also perform a treatment that arbitrarily combines the above-described energy application forms.
- the surgeon can adjust the output of the energy transmission member 120 so that, for example, energy of 100 ° C. or less is applied to the blood vessel V.
- the surgeon controls, for example, a range in which energy is applied within an arbitrary range of 0 ° to 360 ° (range in the direction indicated by arrow a1 in FIG. 4) of the cross section of the blood vessel V. Can do.
- the surgeon can control the range in which the surrounding nerve Sa is damaged within a range of 0% to 100% of the entire surrounding nerve Sa, and can adjust the effect of enhancing the peristaltic movement of the intestinal tract.
- the medical device 100 may include one or more expandable structures near the distal end portion of the medical device 100.
- the surgeon expands the expandable structure in the blood vessel V and temporarily fixes the expandable structure to the blood vessel wall, so that the medical device 100 is parallel to the lumen of the blood vessel. It can be held at a predetermined position in the (blood vessel extending direction).
- the expandable structure may be configured integrally with the catheter body 110 or may be configured as a separate body (separate device) from the catheter body 110.
- a part of the catheter body 110 is configured to be expandable.
- the vicinity of the distal end portion of the catheter body 110 can be formed of a material having self-expandability and the like.
- the expandable structure is configured separately from the catheter body 110, for example, the expandable structure includes a shaft formed with a lumen through which the medical device 100 can be inserted and protruded toward the distal end, and expansion and contraction. And possible balloons.
- the surgeon when the surgeon performs a treatment using the medical device 100, for example, a position close to a predetermined site in the circumferential direction of the blood vessel V from the center position C1 on the transverse section of the blood vessel V (eccentric from the center position C1).
- the central position of the medical device 100 may be disposed at the position).
- the surgeon can effectively apply energy to the peripheral nerve Sa from any position in the circumferential direction of the blood vessel V.
- the medical device 100 can be appropriately provided with a positioning mechanism for arranging the medical device 100 as described above.
- the positioning mechanism can be constituted by a part of the catheter main body or a balloon similarly to the expandable structure, for example.
- the medical device 100 may include one or more sensors that enable temperature measurement near the distal end of the medical device 100.
- the surgeon can control the output of energy based on the measurement result of the sensor.
- the surgeon appropriately controls the output of energy based on the measurement result of the sensor, so that the effect of promoting peristaltic movement due to insufficient energy to be imparted is insufficient or excessive energy is imparted to the blood vessel V.
- the formation of a stenosis or the like in the blood vessel V can be prevented.
- the medical device used for the treatment method is not particularly limited in its specific structure and arrangement of members as long as energy can be applied in the blood vessel.
- omission of each member (structure) of the medical device described with reference to the drawings, use of other additional members not specifically described, modification to a device other than the catheter device, and the like can be appropriately performed.
- the treatment method is specific as long as it includes at least enhancing peristaltic movement of the intestinal tract by performing a treatment that reduces the activity of the autonomic nerve in a blood vessel having a peripheral nerve that performs innervation of the patient's intestinal tract.
- a procedure is not particularly limited.
- 100 medical device catheter device
- 110 catheter body 120 energy transmission member
- 200 guide wire 300 guide catheter
- V blood vessels Va superior mesenteric artery (blood vessel), Vb celiac artery (blood vessel), Vc inferior mesenteric artery (blood vessel), Sa Peripheral nerve.
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgical Instruments (AREA)
Abstract
Description
本発明は、腸管の蠕動運動を亢進させるための処置方法に関する。 The present invention relates to a treatment method for enhancing peristaltic movement of the intestinal tract.
便秘は全世界で高頻度に認められ、人口の25~30%が罹患しているとも言われる一般的な疾病である。慢性便秘は週3回未満の排便、かつ排便困難を呈することと定義される。排便回数の減少は腹部膨満感や腹痛、排便困難や排便時の不快感、頻回少量便などの症状をもたらし、患者の社会活動性や精神衛生性を著しく損なうことが知られている。 Constipation is a common illness that is frequently observed worldwide and is said to affect 25-30% of the population. Chronic constipation is defined as having bowel movements less than 3 times a week and having difficulty in defecation. It is known that the decrease in the number of defecations may cause symptoms such as abdominal fullness and abdominal pain, difficulty of defecation, discomfort during defecation, frequent frequent stools, and so on, which significantly impairs the social activity and mental health of patients.
多くの慢性便秘患者は、医療機関で受診していないが、受診した場合は、排便回数の正常化と便秘による各種腹部症状の改善を目指して薬剤による内服治療が行われる。治療薬として、腸管蠕動運動を促進させる機序の薬剤と、腸管からの分泌を促進もしくは再吸収を抑制し、便を軟化・膨化させる機序の薬剤が従来用いられており、また新規に開発されてきている(例えば、特許文献1を参照)。 Many patients with chronic constipation have not visited a medical institution, but if they do, they are treated with drugs to normalize the number of bowel movements and improve various abdominal symptoms due to constipation. Drugs with a mechanism that promotes intestinal peristalsis and drugs with a mechanism that promotes secretion from the intestinal tract or suppresses reabsorption and softens and swells stools are used as therapeutic agents. (For example, see Patent Document 1).
しかしながら、医療機関で上記のような投薬治療を受けている患者も、その過半は現状の治療に満足していないことが広く知られており、便秘治療において薬剤による治療は十分な解決策となっていない。 However, it is widely known that patients who receive the above-mentioned medication treatment at medical institutions are not satisfied with the current treatment for the majority, and treatment with drugs in constipation treatment is an adequate solution. Not.
また、慢性便秘には原発性(特発性)と続発性のものがある。続発性とは大腸がんなどの器質的疾患によるものや、疼痛緩和のために使用されるオピオイドなどの薬剤によるもの、神経疾患や膠原病などの全身疾患に伴うものなどである。一方で原発性(特発性)便秘は結腸の器質的な異常(拡張など)の有無で器質性便秘と機能性便秘に分けられる。結腸に器質的な異常のない機能性便秘のなかで、大腸の腸蠕動運動が低下し、そのために便の通過時間に遅延がみとめられて便秘を来しているものを「結腸通過時間遅延型便秘」と呼ぶが、こうした患者には内服治療の効果は特に乏しい。内服治療に不応で重症の便秘患者に対しては結腸全摘または部分摘出手術が推奨されることもあるが、その侵襲性から広く受け入れられているとは言い難い。 In addition, chronic constipation includes primary (idiopathic) and secondary. Secondary is caused by organic diseases such as colorectal cancer, caused by drugs such as opioids used for pain relief, and associated with systemic diseases such as neurological diseases and collagen diseases. On the other hand, primary (idiopathic) constipation is divided into organic constipation and functional constipation depending on the presence or absence of organic abnormalities (such as dilation) in the colon. Among functional constipation with no organic abnormalities in the colon, the bowel movement of the large intestine is reduced, so that the stool transit time is delayed and the constipation is seen as `` colon transit time delay type Although referred to as “constipation”, the effectiveness of oral treatment is particularly poor for these patients. Total colectomy or partial excision may be recommended for patients with severe constipation who are refractory to oral treatment, but it is not widely accepted because of its invasiveness.
本発明の発明者らは鋭意検討した結果、腸管の蠕動運動の低下や不足に起因して生じる各種の症状や疾患に対して有効かつ低侵襲に作用する処置方法を見出した。 As a result of intensive studies, the inventors of the present invention have found an effective and minimally invasive treatment method for various symptoms and diseases caused by a decrease or insufficiency of peristaltic movement of the intestinal tract.
本発明に係る処置方法は、患者の腸管の神経支配を行う周囲神経を有する血管内において、自律神経の活性を低下させる処置を行うことにより、腸管の蠕動運動を亢進させることを含む。 The treatment method according to the present invention includes enhancing peristaltic movement of the intestinal tract by performing a treatment that reduces the activity of the autonomic nerve in a blood vessel having a peripheral nerve that performs innervation of the patient's intestinal tract.
上記の処置方法によれば、患者の腸管の蠕動運動を亢進させることができる。 According to the above treatment method, the peristaltic movement of the patient's intestinal tract can be enhanced.
以下、添付した図面を参照しながら、本発明の実施形態を説明する。なお、以下の説明は特許請求の範囲に記載される技術的範囲や用語の意義を限定するものではない。また、図面の寸法比率は説明の都合上誇張されており、実際の比率とは異なる場合がある。 Hereinafter, embodiments of the present invention will be described with reference to the accompanying drawings. In addition, the following description does not limit the meaning of the technical scope and terms described in the claims. In addition, the dimensional ratios in the drawings are exaggerated for convenience of explanation, and may differ from actual ratios.
図1には、実施形態に係る処置方法(以下、「処置方法」とする)の手順をフローチャートにより概略的に示している。図1に示すように、処置方法は、概説すると、所定の医療デバイスを、処置を実施する血管内に送達すること(S11)と、血管内において処置を実施すること(S12)と、を含む。 FIG. 1 schematically shows a procedure of a treatment method (hereinafter referred to as “treatment method”) according to the embodiment in a flowchart. As shown in FIG. 1, the treatment method generally includes delivering a predetermined medical device into a blood vessel for performing the treatment (S11) and performing the treatment within the blood vessel (S12). .
図2を参照して、処置方法を実施する血管Vについて説明する。図2において、符号VRは右腎動脈を示し、符号VLは左腎動脈を示している。また、符号Vaは、上腸間膜動脈、符号Vbは腹腔動脈、符号Vcは下腸間膜動脈を示している。 Referring to FIG. 2, the blood vessel V that performs the treatment method will be described. In FIG. 2, the symbol VR indicates the right renal artery, and the symbol VL indicates the left renal artery. Reference sign Va indicates the superior mesenteric artery, reference sign Vb indicates the celiac artery, and reference sign Vc indicates the inferior mesenteric artery.
処置方法が適用される血管Vは、実施形態に係る所定の処置(例えば、後述するエネンルギーの付与)が施されることにより、患者(被験者)の腸管の蠕動運動を亢進することが可能であれば特に限定されないが、例えば、上腸間膜動脈Va、腹腔動脈Vb、下腸間膜動脈Vcのうちの少なくとも一つを好適に選択することができる。 The blood vessel V to which the treatment method is applied may be able to enhance the peristaltic movement of the intestinal tract of the patient (subject) by being subjected to the predetermined treatment according to the embodiment (for example, application of energy described later). Although not particularly limited, for example, at least one of the superior mesenteric artery Va, the celiac artery Vb, and the inferior mesenteric artery Vc can be suitably selected.
また、血管Vにおいて処置が施される処置部位(範囲、位置等)についても、腸管の蠕動運動を亢進させることが可能な限り、特に限定されない。例えば、血管V内において、血管Vの走行方向(延在方向)の任意の範囲(部位)に対して処置を実施してもよいし、血管Vの周方向(横断面の周方向)の任意の範囲(部位)に対して処置を実施してもよい。また、処置は、同一の血管Vの複数の処置部位に対して複数回の処置を実施してもよいし、異なる血管Vの任意の処置部位に対して複数回の処置を実施してもよい。つまり、本実施形態に係る処置方法は、少なくとも一回の処置を実施することにより患者の腸管の蠕動運動を亢進させることが可能な限り、処置対象となる血管の種類、血管の処置部位、処置の具体的な内容、処置に使用される装置や器具等は限定されない。 Also, the treatment site (range, position, etc.) where treatment is performed in the blood vessel V is not particularly limited as long as the peristaltic movement of the intestinal tract can be enhanced. For example, in the blood vessel V, treatment may be performed on an arbitrary range (part) in the traveling direction (extending direction) of the blood vessel V, or in the circumferential direction of the blood vessel V (circumferential direction in the cross section). Treatment may be performed on the range (site). In addition, the treatment may be performed a plurality of times for a plurality of treatment sites of the same blood vessel V, or may be performed a plurality of times for any treatment site of different blood vessels V. . That is, the treatment method according to the present embodiment is capable of enhancing the peristaltic movement of the patient's intestinal tract by performing at least one treatment, so that the type of blood vessel to be treated, the treatment site of the blood vessel, the treatment There are no particular restrictions on the specific contents, devices and instruments used for the treatment.
次に、図3および図4を参照して、本実施形態に係る処置方法および処置方法に使用される医療デバイス100について説明する。以下では、処置対象となる血管Vとして上腸間膜動脈Vaに対して処置を実施する例を説明する。なお、以下に説明する処置手順は一例に過ぎず、例えば、一部の手順や特に説明のない手順等については、医療分野において公知の手順を適宜採用することが可能である。
Next, with reference to FIG. 3 and FIG. 4, the
図3は、処置方法を実施している際の血管V内の様子を模式的に示す断面図(縦断面図)であり、図4は、処置方法を実施している際の血管V内の様子を模式的に示す断面図(横断面図)である。図3および図4において、血管Vの走行方向を矢印Xで示し、血管Vの走行方向と直交する奥行方向を矢印Yで示し、血管Vの走行方向および血管Vの奥行方向の各々に対して直交する方向を矢印Zで示す。 FIG. 3 is a cross-sectional view (longitudinal cross-sectional view) schematically showing a state in the blood vessel V when the treatment method is being performed, and FIG. 4 is a view inside the blood vessel V when the treatment method is being performed. It is sectional drawing (transverse sectional view) which shows a mode typically. 3 and 4, the traveling direction of the blood vessel V is indicated by an arrow X, the depth direction orthogonal to the traveling direction of the blood vessel V is indicated by an arrow Y, and each of the traveling direction of the blood vessel V and the depth direction of the blood vessel V is illustrated. An orthogonal direction is indicated by an arrow Z.
本実施形態に係る処置では、医師等の術者(以下、「術者」とする)は、患者の腸管の神経支配を行う周囲神経(神経叢)Saを有する血管V内において、自律神経の活性を低下させる処置を行うことにより、腸管の蠕動運動を亢進させる。術者は、このような処置を行うことにより、患者の便秘および/または腸管の蠕動運動の異常に起因する腹部膨満感、腹痛、会陰部の不快感、頻回便のうちの少なくとも一つの症状(患者の便秘の緩和および/または腸管の蠕動運動の異常に起因する症状群の中の少なくとも一つ)の緩和を促す。 In the treatment according to the present embodiment, an operator such as a doctor (hereinafter referred to as “operator”) has an autonomic nerve in a blood vessel V having a peripheral nerve (plexus) Sa that performs innervation of the intestinal tract of the patient. By performing treatment to reduce the activity, peristaltic movement of the intestinal tract is increased. By performing such treatment, the surgeon can perform at least one symptom of abdominal bloating, abdominal pain, perineal discomfort, and frequent stool due to abnormal constipation and / or peristaltic movement of the intestinal tract. Helps alleviate (at least one of a group of symptoms caused by an alleviation of patient constipation and / or abnormal intestinal peristalsis).
前述したように処置対象となる血管Vとしては、上腸間膜動脈Va、腹腔動脈Vb、下腸間膜動脈Vcのうちの少なくとも一つを選択することが好ましい。そして、術者は、処置として、一つの周囲神経Saまたは複数の周囲神経Saにエネルギーを付与する。それにより、術者は、周囲神経Saを障害し、周囲神経Saによる消化管への自律神経伝達を完全にまたは一部遮断することにより、腸管の蠕動運動を亢進させる。 As described above, it is preferable to select at least one of the superior mesenteric artery Va, the celiac artery Vb, and the inferior mesenteric artery Vc as the blood vessel V to be treated. Then, the surgeon applies energy to one surrounding nerve Sa or a plurality of surrounding nerves Sa as a treatment. Thus, the surgeon increases the peristaltic movement of the intestinal tract by damaging the peripheral nerve Sa and completely or partially blocking the autonomic nerve transmission to the digestive tract by the peripheral nerve Sa.
周囲神経Saを有する血管V内において自律神経の活性を低下させる処置を行うことにより、腸管の蠕動運動が活性化する理由として、次のような点が考えられる。血管V内から付与したエネルギーにより、周囲神経Saを障害し、周囲神経Saによる消化管への自律神経伝達を完全にまたは一部遮断すると、交感神経系、副交感神経系のうち交感神経系が相対的に減弱して副交感優位になる。また、中枢からの神経伝達が遮断されることにより、末梢で腸管運動を自律的に制御しているが腸管神経系が優位になり、腸管の蠕動運動が活性化する。また、腸管の蠕動運動が活性化すると、結腸通過時間が促進・正常化するため、便秘および/または腸管の蠕動運動の異常に起因する腹部膨満感、腹痛、会陰部の不快感、頻回便のうちの少なくとも一つの症状の緩和が促される。特に、本実施形態に係る処置方法によれば、結腸に器質的な異常のない機能性便秘のなかで、大腸の腸蠕動運動が低下し、そのために便の通過時間に遅延がみとめられて便秘を来している結腸通過時間遅延型便秘の症状の緩和を好適に促すことができる。 The following points can be considered as reasons why the peristaltic movement of the intestinal tract is activated by performing a treatment for reducing the activity of the autonomic nerve in the blood vessel V having the surrounding nerve Sa. When the peripheral nerve Sa is damaged by the energy applied from within the blood vessel V, and the autonomic nerve transmission to the digestive tract by the peripheral nerve Sa is completely or partially blocked, the sympathetic nervous system is relative to the sympathetic nervous system and parasympathetic nervous system. It becomes attenuated and becomes parasympathetic dominant. In addition, by blocking nerve transmission from the center, intestinal motility is controlled autonomously in the periphery, but the enteric nervous system becomes dominant, and peristaltic movement of the intestinal tract is activated. In addition, activation of the intestinal peristaltic movement promotes and normalizes the colon transit time, so that abdominal fullness, abdominal pain, perineal discomfort, frequent stool due to abnormal constipation and / or intestinal peristaltic movement Alleviation of at least one of the symptoms is promoted. In particular, according to the treatment method according to the present embodiment, intestinal peristalsis movement of the large intestine is reduced in functional constipation with no organic abnormality in the colon, and therefore, the stool passage time is delayed and constipation is observed. It is possible to favorably alleviate the symptoms of colon transit time delayed constipation.
術者は、例えば、図3および図4に示すように、所定の医療デバイス100を使用して処置を実施することができる。具体的には、術者は、エネルギーを付与可能なエネルギー伝達部材120を備える医療デバイス100を血管V内に配置した状態で、医療デバイス100を作動させることにより処置を実施することができる。図3および図4において、医療デバイス100により付与するエネルギーを破線付き矢印で概略的に示す。
The surgeon can perform treatment using a predetermined
医療デバイス100としては、長尺状のカテーテル本体110と、カテーテル本体110の先端部(血管V内への挿入方向側の端部付近)に配置されたエネルギー伝達部材120と、を備えるカテーテルデバイスを使用することができる。なお、カテーテル本体110は、カテーテル本体110の長軸方向(延在方向)に延びるルーメン(図示省略)と、カテーテル本体110の基端部(血管V内への挿入方向と反対側の端部付近)に配置されたハブ(図示省略)と、を備えている。医療デバイス100は、ルーメンおよびハブを通じて、ガイドワイヤ200等の医療器具を挿通させたり、プライミング液等の液体を流通させたりすることが可能である。なお、医療デバイス100の具体的な構造については、公知のカテーテルデバイス(例えば、アブレーションデバイス等の治療用カテーテルデバイス)の構造を適宜採用することが可能である。
As the
医療デバイス100が備えるエネルギー伝達部材120は、例えば、単純高周波、双極高周波、高密度焦点式超音波、超音波、マイクロ波、光、熱、寒放射線、工学療法、磁気的、電気的、電磁的、冷凍療法、プラズマ、機械的エネルギー、化学的エネルギー、動力学的エネルギー、潜在的エネルギー、原子核的エネルギー、弾性的エネルギー、流体力学的エネルギーからなる群のうちの少なくとも一つを血管Vの内側から付与するように構成することができる。
The
エネルギー伝達部材120の動作は、例えば、図示省略するコントローラ(制御装置)を介して制御することができる。コントローラとしては、例えば、CPUと記憶部を備える公知の制御用デバイスを利用することができる。記憶部は、各種のプログラムやデータを格納するROM、作業領域として一時的にプログラムやデータを記憶するRAM、各種のプログラムやデータを格納可能なハードディスク等を備える。上記記憶部には、医療デバイス100の動作制御に必要な一連のプログラムを記憶させることができる。なお、エネルギー伝達部材120は、図示省略する電源部と電気的に接続されており、電源部を介して動作のON/OFF、血管Vに付与するエネルギーの大きさ等を制御することができる。また、エネルギー伝達部材120への動作指令の送信形態としては、例えば、電気通信線を介した有線によるもの、電気通信線を介さない無線によるもの、制御装置に組み込まされた操作部を介した術者等からの入力に基づいて送信を行うもの、制御装置とは別の装置として準備された外部通信手段等からの入力に基づいて送信を行うもの等などを挙げることが可能であるが、具体的な形態は特に限定されない。また、本実施形態に係る処置は、例えば、術者による作業を代替する処置用ロボット等の医療デバイスにより実施させてもよい。この場合、処置は、手術室等の医療現場において術者等が処置用ロボットを制御してもよいし、遠隔地において処置用ロボットを制御するようにしてもよい。
The operation of the
医療デバイス100が備えるカテーテル本体110は、エネルギー伝達部材120を上腸間膜動脈Va、腹腔動脈Vb、または下腸間膜動脈Vcへ送達するために、患者の血管の湾曲部または屈曲部に追従して移動可能であるように構成することが好ましい。カテーテル本体110は、上記のような性能を備え得るようにするために、例えば、柔軟性、トルク伝達性、耐キンク性等を備える公知のカテーテルデバイスに使用される各種材料や構造等を採用することができる。
The
術者は、医療デバイス100を血管Vに挿入する際、例えば、図3に示すように、ガイドワイヤ200およびガイドカテーテル300を使用することができる。ガイドワイヤ200およびガイドカテーテル300は、医療分野において公知のものを使用することができる。また、術者は、例えば、大腿動脈、腹部大動脈等を介して医療デバイス100を血管V(上腸間膜動脈Va、腹腔動脈Vb、下腸間膜動脈Vcのうちの任意の血管)の所望の位置(処置部位)まで送達することができる。
When inserting the
術者は、図3に示すように、血管V内の所望の位置までエネルギー伝達部材120を送達した後、エネルギー伝達部材120を作動させて、血管V内から血管Vの外側に存在する周囲神経Saに対してエネルギーを付与する。
As shown in FIG. 3, the surgeon delivers the
術者は、処置を行う際、例えば、血管Vの全周方向(血管Vの内壁に沿って間欠がないような形態)、血管Vの周方向の一部(血管Vの内壁の周方向の一部のみ、例えば、半周未満の形態)、血管Vの半周(血管Vの内壁の周方向の半分の形態)、線形状(血管Vの内壁の周方向に一定の長さで連続した形態)、および放射状(血管Vの横断面の中心から血管Vの径方向外方へ離間する方向)の少なくとも一つの形態でエネルギーを付与することができる。また、術者は、上記の各エネルギーの付与形態を任意に組み合わせた処置を実施することも可能である。 When performing treatment, for example, the surgeon, for example, in the entire circumferential direction of the blood vessel V (a form in which there is no intermittence along the inner wall of the blood vessel V), a part of the circumferential direction of the blood vessel V (the circumferential direction of the inner wall of the blood vessel V) Only a part, for example, a form less than a half circumference), a half circumference of the blood vessel V (a half form in the circumferential direction of the inner wall of the blood vessel V), a linear shape (a form continuous in a certain length in the circumferential direction of the inner wall of the blood vessel V) , And energy (in a direction away from the center of the cross section of the blood vessel V outward in the radial direction of the blood vessel V). In addition, the surgeon can also perform a treatment that arbitrarily combines the above-described energy application forms.
術者は、処置を行う際、例えば、100℃以下のエネルギーを血管Vに付与するように、エネルギー伝達部材120の出力を調整することができる。
When performing the treatment, the surgeon can adjust the output of the
また、術者は、処置を行う際、例えば、血管Vの横断面の0°~360°の任意の範囲(図4の矢印a1で示す方向における範囲)においてエネルギーを付与する範囲を制御することができる。術者は、周囲神経Saが障害する範囲を周囲神経Saの全体の0%~100%の範囲で制御し、腸管の蠕動運動の亢進効果を調整することができる。 In addition, when performing the treatment, the surgeon controls, for example, a range in which energy is applied within an arbitrary range of 0 ° to 360 ° (range in the direction indicated by arrow a1 in FIG. 4) of the cross section of the blood vessel V. Can do. The surgeon can control the range in which the surrounding nerve Sa is damaged within a range of 0% to 100% of the entire surrounding nerve Sa, and can adjust the effect of enhancing the peristaltic movement of the intestinal tract.
また、医療デバイス100は、医療デバイス100の先端部付近に拡張可能構造を1つ以上備えていてもよい。このように医療デバイス100が構成される場合、術者は、拡張可能構造を血管V内で拡張させて血管壁に一時的に固定することにより、医療デバイス100を血管の内腔と平行な方向(血管の延在方向)における所定の位置に保持することが可能になる。拡張可能構造は、例えば、カテーテル本体110と一体的に構成してもよいし、カテーテル本体110とは別体(別のデバイス)として構成してもよい。拡張可能構造をカテーテル本体110に一体的に構成する場合、例えば、カテーテル本体110の一部が拡張可能に構成される。この場合、例えば、カテーテル本体110の先端部付近を、自己拡張性等を備える材料で形成することができる。また、拡張可能構造をカテーテル本体110とは別体で構成する場合、例えば、拡張可能構造は、医療デバイス100の挿通および先端側への突出が可能なルーメンが形成されたシャフトと、拡張および収縮可能なバルーンと、を備えるバルーンカテーテルで構成することができる。
Further, the
また、術者は、医療デバイス100を使用した処置を実施する際、例えば、血管Vの横断面上における中心位置C1から血管Vの周方向の所定の部位に接近した位置(中心位置C1から偏心した位置)に医療デバイス100の中心位置を配置してもよい。術者は、医療デバイス100をこのように配置することにより、血管Vの周方向の任意の位置から周囲神経Saに対して効果的にエネルギーを付与することが可能になる。なお、医療デバイス100には、上記のように医療デバイス100を配置するための位置決め機構を適宜設けることが可能である。位置決め機構は、例えば、拡張可能構造と同様にカテーテル本体の一部で構成したり、バルーンで構成したりすることができる。
Further, when the surgeon performs a treatment using the
また、医療デバイス100は、医療デバイス100の先端部付近に温度測定を可能にするセンサーを1つ以上備えていてもよい。このように医療デバイス100が構成される場合、術者は、センサーの測定結果に基づいてエネルギーの出力を制御することが可能である。術者は、センサーの測定結果に基づきエネルギーの出力を適切に制御することにより、付与するエネルギーが不足して蠕動運動を亢進する効果が十分に発現されなかったり、血管Vに過度なエネルギーが付与されて血管Vに狭窄部等が形成されたりすることを防止することができる。なお、上記センサーの種類、配置する位置、個数等について特に制限はない。
Further, the
以上、実施形態を通じて本発明に係る処置方法を説明したが、本発明は明細書において説明した内容のみに限定されるものでなく、特許請求の範囲の記載に基づいて適宜変更することが可能である。 Although the treatment method according to the present invention has been described above through the embodiments, the present invention is not limited to the contents described in the specification, and can be appropriately changed based on the description of the scope of claims. is there.
処置方法に使用される医療デバイスは、血管内においてエネルギーを付与可能な限り、その具体的な構造や部材の配置等は特に限定されない。例えば、図示により説明した医療デバイスの各部材(構造)の設置の省略、特に説明されなかったその他の付加的な部材の使用、カテーテルデバイス以外の形態のデバイスへの改変等は適宜に行い得る。 The medical device used for the treatment method is not particularly limited in its specific structure and arrangement of members as long as energy can be applied in the blood vessel. For example, omission of each member (structure) of the medical device described with reference to the drawings, use of other additional members not specifically described, modification to a device other than the catheter device, and the like can be appropriately performed.
また、処置方法は、患者の腸管の神経支配を行う周囲神経を有する血管内において、自律神経の活性を低下させる処置を行うことにより、腸管の蠕動運動を亢進させることを少なくとも含む限り、具体的な手順は特に限定されない。 Further, the treatment method is specific as long as it includes at least enhancing peristaltic movement of the intestinal tract by performing a treatment that reduces the activity of the autonomic nerve in a blood vessel having a peripheral nerve that performs innervation of the patient's intestinal tract. Such a procedure is not particularly limited.
100 医療デバイス(カテーテルデバイス)、
110 カテーテル本体、
120 エネルギー伝達部材、
200 ガイドワイヤ、
300 ガイドカテーテル、
V 血管、
Va 上腸間膜動脈(血管)、
Vb 腹腔動脈(血管)、
Vc 下腸間膜動脈(血管)、
Sa 周囲神経。
100 medical device (catheter device),
110 catheter body,
120 energy transmission member,
200 guide wire,
300 guide catheter,
V blood vessels,
Va superior mesenteric artery (blood vessel),
Vb celiac artery (blood vessel),
Vc inferior mesenteric artery (blood vessel),
Sa Peripheral nerve.
Claims (20)
前記処置は、一つの前記周囲神経または複数の前記周囲神経にエネルギーを付与することにより前記周囲神経を障害し、前記周囲神経による消化管への自律神経伝達を完全にまたは一部遮断することにより前記腸管の蠕動運動を亢進させる、請求項1に記載の処置方法。 The blood vessel is at least one of superior mesenteric artery, celiac artery, inferior mesenteric artery,
The treatment includes damaging the surrounding nerve by applying energy to one of the surrounding nerves or a plurality of the surrounding nerves, and completely or partially blocking autonomic nerve transmission to the digestive tract by the surrounding nerves. The treatment method according to claim 1, wherein peristaltic movement of the intestinal tract is enhanced.
前記カテーテル本体は、前記エネルギー伝達部材を上腸間膜動、腹腔動脈、または下腸間膜動脈へ送達するために、前記患者の血管の湾曲部または屈曲部に追従して移動可能である、請求項14に記載の処置方法。 The catheter device includes a long catheter body, and the energy transmission member disposed at a distal end portion of the catheter body,
The catheter body is movable following a curved or bent portion of the patient's blood vessel to deliver the energy transfer member to the superior mesenteric movement, celiac artery, or inferior mesenteric artery, The treatment method according to claim 14.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2018/012839 WO2019186786A1 (en) | 2018-03-28 | 2018-03-28 | Treatment method |
| PCT/JP2019/013892 WO2019189702A1 (en) | 2018-03-28 | 2019-03-28 | Treatment method and medical device |
| JP2020511056A JPWO2019189702A1 (en) | 2018-03-28 | 2019-03-28 | Treatment methods and medical devices |
| US17/032,897 US20210007799A1 (en) | 2018-03-28 | 2020-09-25 | Treatment Method and Medical Device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2018/012839 WO2019186786A1 (en) | 2018-03-28 | 2018-03-28 | Treatment method |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2019/013892 Continuation WO2019189702A1 (en) | 2018-03-28 | 2019-03-28 | Treatment method and medical device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2019186786A1 true WO2019186786A1 (en) | 2019-10-03 |
Family
ID=68059563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2018/012839 Ceased WO2019186786A1 (en) | 2018-03-28 | 2018-03-28 | Treatment method |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2019186786A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013134541A2 (en) * | 2012-03-08 | 2013-09-12 | Medtronic Ardian Luxembourg Sarl | Gastrointestinal neuromodulation and associated systems and methods |
| JP2014525786A (en) * | 2011-07-22 | 2014-10-02 | コーニンクレッカ フィリップス エヌ ヴェ | Ablation device |
| JP2015119831A (en) * | 2013-12-24 | 2015-07-02 | テルモ株式会社 | Ablation catheter |
| WO2016039394A1 (en) * | 2014-09-12 | 2016-03-17 | テルモ株式会社 | Ablation catheter |
-
2018
- 2018-03-28 WO PCT/JP2018/012839 patent/WO2019186786A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014525786A (en) * | 2011-07-22 | 2014-10-02 | コーニンクレッカ フィリップス エヌ ヴェ | Ablation device |
| WO2013134541A2 (en) * | 2012-03-08 | 2013-09-12 | Medtronic Ardian Luxembourg Sarl | Gastrointestinal neuromodulation and associated systems and methods |
| JP2015119831A (en) * | 2013-12-24 | 2015-07-02 | テルモ株式会社 | Ablation catheter |
| WO2016039394A1 (en) * | 2014-09-12 | 2016-03-17 | テルモ株式会社 | Ablation catheter |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220331554A1 (en) | Catheters with enhanced flexibility and associated devices, systems, and methods | |
| US9486355B2 (en) | Selective accumulation of energy with or without knowledge of tissue topography | |
| CN102438690B (en) | Device and system for achieving intravascular heat-induced renal neuromodulation | |
| EP4074274B1 (en) | Low profile catheter assemblies | |
| US20220160424A1 (en) | Catheter apparatuses for modulation of nerves in communication with the pulmonary system and associated systems and methods | |
| JP2009535188A (en) | Control of arterial smooth muscle tone | |
| WO2023072154A1 (en) | Electrode balloon catheter | |
| US9399115B2 (en) | Catheters with enhanced flexibility and associated devices, systems, and methods | |
| JP2017507725A (en) | Catheter with independent radial expansion member and related devices, systems and methods | |
| JP7186467B2 (en) | Medical devices for guiding devices and denervation | |
| ES2725888T3 (en) | Ultrasonic catheter for renal denervation | |
| US20210007799A1 (en) | Treatment Method and Medical Device | |
| WO2019186786A1 (en) | Treatment method | |
| WO2021033275A1 (en) | Catheter device and treatment method | |
| WO2020250417A1 (en) | Catheter device and treatment method | |
| CN118303954A (en) | Ultrasonic catheter device focused through superfine cavity | |
| CN118216976A (en) | A shock wave balloon with adjustable direction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18913093 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18913093 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |